Amylin Pharmaceuticals LLC

Amylin Pharmaceuticals — Proxy Contest (May 2009)

43 slides from Amylin Pharmaceuticals's proxy contest presentation, May 5, 2009

  1. Slide 1: Amylin Pharmaceuticals: Positioned For Value Creation, Spring 2009

    Amylin Pharmaceuticals, Inc. Positioned For Value Creation Spring 2009

  2. Slide 2: Legal Information

    Legal Information FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about Amylin. Our actual results could differ materially from those discussed due to a number of factors, including: BYETTA, SYMLIN or exenatide once weekly being affected by competition, safety or oth

  3. Slide 3: An Innovation Leader in Diabetes Therapy

    An Innovation Leader in Diabetes Therapy BYETTA® (exenatide) injection Only approved GLP-1 receptor agonist therapy for type 2 diabetes Launched in 2005 Treated over one million patients $678 million in 2008 sales Partnered with Lilly Added to the ADA treatment guidelines in 2008 SYMLIN® (pramlintid

  4. Slide 4: Accountable Leadership: Taking Action To Create Shareholder Value

    Accountable Leadership: Taking Action To Create Shareholder Value Topic Restructured R&D and G&A (25% headcount reduction) Restructured as a specialty sales force (35% headcount reduction) Comprehensive restructuring of Lilly collaboration Focus organization to profitably launch exenatide once weekl

  5. Slide 5: Amylin Has a History of Innovation and is Poised for Growth

    BYETTA Added to ADA Treatment Guidelines Amylin Has a History of Innovation and is Poised for Growth Launched two first-in-class, internally-developed diabetes therapies Business model has driven innovation and will provide operating and financial leverage Commenced Manufacturing Exenatide Once Week

  6. Slide 6: Agenda

    Agenda Choosing the Right Team for Amylin The Diabetes and Obesity Epidemics Drive Our Opportunity Exenatide Once Weekly Launch Strategy Financial Strength and Discipline to Create Value 4

  7. Slide 7: The Diabetes and Obesity Epidemics Drive Our Opportunity

    The Diabetes and Obesity Epidemics Drive Our Opportunity Source: CDC BRFSS 2005 and US Market Data from ADA “With a new diagnosis every 21 seconds, diabetes is the fastest growing disease in America” – American Diabetes Association 5%–6% <5% >8% 7%–8% No Data 6%–7% >30% 10%–14% <10% 25%-29% 20%–24%

  8. Slide 8: Exenatide Once Weekly Targets Unmet Needs

    Exenatide Once Weekly Targets Unmet Needs Once-weekly dosing Convenient dosing No major hypoglycemia events Minimal hypoglycemic risk Recent meta-analysis of BYETTA data indicated no increased CV risk Weight loss (6.2 – 9.5 lbs) Reduction in A1C (1.7% to 2.0%) DURATION-1 and DURATION-2 Exenatide Onc

  9. Slide 9: Efficacy and Convenience of Exenatide Once Weekly Broaden Market Opportunity

    ~24 million people with diabetes Source: US Market Data from CDC, IMS, and Amylin estimates *Latest twelve months ended March 31, 2009 net product sales: BYETTA $678 million, SYMLIN $88 million Undiagnosed Diet & Exercise Oral Agents Insulin 6 million 3 million 10 million 5 million Single Multiple S

  10. Slide 10: Amylin Consistently Responds to Regulatory Challenges in a Timely, Evidence-Based Manner

    Amylin Consistently Responds to Regulatory Challenges in a Timely, Evidence-Based Manner (1) Noel, Braun, Patterson and Bloomgren, online February 2009, Diabetes Care (2) Dore, Seeger and Chan; Current Medical Research and Opinion, Vol 25, No. 4, 2009 Use of extensive clinical data across entire exe

  11. Slide 11: Amylin has a Track Record of Successfully Navigating the Complex Regulatory Environment

    Proactive pre-clinical strategy Exenatide Once Weekly Building on database and experience of BYETTA: >1 million patients NDA submitted as planned Line extension (505(b)1) regulatory strategy confirmed with the FDA at the pre-NDA meeting DURATION-1: pivotal safety and efficacy DURATION-1 extension: c

  12. Slide 12: Progressing on Milestones for Value Creation

    Progressing on Milestones for Value Creation 1Q 2Q 3Q 4Q 2009 2010 Submit exenatide once weekly NDA DURATION-1 extension for manufacturing comparability DURATION-2 Results DURATION-3 Results Pramlintide / Metreleptin Phase 2B Results Davalintide (AC2307) Phase 2 Results Finalize Obesity Development

  13. Slide 13: Amylin / Lilly Relationship Strengthened

    Amylin / Lilly Relationship Strengthened Focused and Aligned on BYETTA and Exenatide Once Weekly Shared Vision and Goals Senior leaders of both companies fully engaged and aligned Exenatide molecule is vitally important to both companies Recent commitment to develop next generation pen for exenatide

  14. Slide 14: Agenda

    Agenda Choosing the Right Team for Amylin The Diabetes and Obesity Epidemics Drive Our Opportunity Exenatide Once Weekly Launch Strategy Financial Strength and Discipline to Create Value 12

  15. Slide 15: Improved Amylin / Lilly Relationship Will Drive Operating Results

    Improved Amylin / Lilly Relationship Will Drive Operating Results Single marketing, development and medical teams Single accountability for decision making and execution Located in San Diego Amylin specialty sales force targets key 30K physicians Represent >70% of revenue for BYETTA Increase call fr

  16. Slide 16: Exenatide Once Weekly has the Potential to Fundamentally Change the Treatment of Type 2 Diabetes

    Exenatide Once Weekly has the Potential to Fundamentally Change the Treatment of type 2 Diabetes Clinical Science and Market Experience Not all GLP-1 agonists are created equal Considerable exenatide clinical and market experience data Development Strategy and Plans DURATION series designed to show

  17. Slide 17: Agenda

    Agenda Choosing the Right Team for Amylin The Diabetes and Obesity Epidemics Drive Our Opportunity Exenatide Once Weekly Launch Strategy Financial Strength and Discipline to Create Value 15

  18. Slide 18: Maintaining Financial Flexibility to Launch Exenatide Once Weekly

    Maintaining Financial Flexibility to Launch Exenatide Once Weekly 2007 – 2009 (Guidance) ($MM) Non-GAAP Operating Expenses (R&D and SG&A Only) Positive Operating Cash Flow by the end of 2010 (1) See Appendix B for a reconciliation of non-GAAP operating expenses to GAAP operating expenses See Appendi

  19. Slide 19: Agenda

    Agenda Choosing the Right Team for Amylin The Diabetes and Obesity Epidemics Drive Our Opportunity Exenatide Once Weekly Launch Strategy Financial Strength and Discipline to Create Value 17

  20. Slide 20: Amylin's Slate Has the Required Operational and Diabetes Experience

    Amylin’s Slate Has the Required Operational and Diabetes Experience Extensive outreach to shareholders by Lead Independent Director Confirmed interest in additional biopharmaceutical operations and commercial experience Entire Board elected annually 8 of 12 nominees on the slate will have joined sin

  21. Slide 21: Proven Leadership With Broad Functional Expertise

    Proven Leadership With Broad Functional Expertise Management & Operations Finance / Accounting / Capital Markets Steven Altman President, QUALCOMM Board member: Juvenile Diabetes Research Foundation, San Diego chapter Daniel Bradbury, CEO Joined in 1994; previously COO 10 years at SmithKline Beecham

  22. Slide 22: Amylin Slate: Broad Diabetes and Operational Experience

    1999 Jay Skyler, M.D., MACP 2006 Steven Altman, J.D. Medical Industry 1 0 2 Diabetes 1994 Joseph Cook 4 6 7 8 4 Eastbourne / Icahn Slate1 2003 Joseph Sullivan, J.D., M.B.A. 2002 James Wilson, M.B.A. 2005 Karin Eastham, M.B.A., C.P.A. 2005 James Gavin, M.D., Ph.D. - Paulo Costa, M.B.A. - Paul Clark,

  23. Slide 23: Amylin Slate: Broad Diabetes and Operational Experience

    2006 Steven Altman, J.D. 1994 Joseph Cook Medical Industry 1 1 2 Diabetes 2005 James Gavin, M.D., Ph.D. 4 5 6 8 3 Icahn Slate1 1999 Jay Skyler, M.D., MACP 2002 James Wilson, M.B.A. 2005 Karin Eastham, M.B.A., C.P.A. 2003 Joseph Sullivan, J.D., M.B.A. - Paulo Costa, M.B.A. - Paul Clark, M.B.A. 2006 D

  24. Slide 24: What Happens When Icahn Gets Board Representation?

    What Happens When Icahn Gets Board Representation? Situations Since 2000 Source: CapIQ, Shark Repellant, public sources as of 27-Apr-2009 Note: Companies listed are situations where Icahn and /or his affiliates obtained board representation since 2000. Performance is measured from the day Icahn or a

  25. Slide 25: Your Proxy Vote is Critical

    Your Proxy Vote is Critical: The Next 12 Months are Key to Future Shareholder Value Improve Operations Vote FOR the Board’s Superior Nominees on the BLUE Card Directors with relevant operational, regulatory and diabetes experience Added two leading industry professionals with biopharmaceutical sales

  26. Slide 26: Appendix A: Supplementary Materials

    Appendix A: Supplementary Materials 23

  27. Slide 27: Leverage Strong Financial Position

    No near term financing need Attractive cost of debt with long-dated maturities Significant cash position will allow us to fund next stage growth and commercialization Pursue obesity corporate development activities efficiently to conserve capital Leverage Strong Financial Position 898 Total L+100 21

  28. Slide 28: Amylin vs. ImClone: Very Different Companies

    Amylin vs. ImClone — Very Different Companies, Both Structurally and Operationally Amylin market cap as of 4/29/09; ImClone market cap represents sale price on 11/21/08 Amylin values are 2008A; ImClone values are 2007A. Amylin books BYETTA end-market sales and pays Lilly a collaborative profit split

  29. Slide 29: Appendix B: Reconciliation Tables

    Appendix B: Reconciliation Tables 26

  30. Slide 30: GAAP / Non-GAAP Reconciliation Tables

    GAAP / Non-GAAP Reconciliation Tables (25) (22) Other non-cash compensation Less non-cash expenses: 500 - 525 579 568 Non-GAAP operating expenses (40) (30) (19) Depreciation and amortization (60) (55) (59) Stock-based compensation 600 - 625 688 668 GAAP operating expenses 2009E1 2008 2007 Operating

  31. Slide 31: Appendix C: Director Biographies

    Appendix C: Director Biographies 28

  32. Slide 32: Adrian Adams

    Adrian Adams Strong biotechnology, operations and commercial experience Mr. Adams has significant biotechnology execution expertise serving as CEO and director of Sepracor, Inc. Previously he was President and CEO, Kos Pharmaceuticals and President and CEO of Novartis-UK He has more than 30 years of

  33. Slide 33: Steven Altman, J.D.

    Steven Altman, J.D. Significant management and licensing experience Mr. Altman is President of QUALCOMM having worked through several departments in QUALCOMM Help lead QUALCOMM from private company to major digital wireless telecommunications player Mr. Altman has been a board member of the San Dieg

  34. Slide 34: Teresa Beck, M.B.A.

    Teresa Beck, M.B.A. Strong finance and accounting background Ms. Beck has strong financial skills having been CFO of American Stores Company, controller of Steiner Financial Corporation and an audit manager at Ernst & Young Her financial and accounting expertise are critical for advising Amylin’s ma

  35. Slide 35: Daniel Bradbury, D.M.S.

    Daniel Bradbury, D.M.S. Strong leadership skills and operating experience Mr. Bradbury has significant operational experience in the diabetes industry serving as our CEO and previously as our COO and President He was critical in the development, approval and commercialization of BYETTA and SYMLIN Gi

  36. Slide 36: Paul Clark, M.B.A.

    Paul Clark, M.B.A. Extensive experience in commercial pharmaceutical products Mr. Clark was the CEO, President and Chairman of the Board at Icos Corporation He has over 30 years of marketing and operating experience in the pharmaceutical industry 14 years at Abbott retiring as EVP and Board member W

  37. Slide 37: Joseph Cook

    Joseph Cook Extensive biotech and pharmaceutical operations leadership Mr. Cook has strong operating experience in the diabetes industry having been a former CEO of Amylin and a former Group Vice President at Eli Lilly Mr. Cook’s relationships were essential to establishing the partnership with Eli

  38. Slide 38: Paulo Costa, M.B.A.

    Paulo Costa, M.B.A. Significant operations, regulatory and commercial expertise Mr. Costa was the President & CEO of Novartis U.S. Mr. Costa worked at J&J for 30 years focusing on operations, sales and marketing as a member of senior management He has over 20 years of general management experience,

  39. Slide 39: Karin Eastham, M.B.A., C.P.A.

    Karin Eastham, M.B.A., C.P.A. Strong financial background in the biopharmaceutical industry Ms. Eastham served as the EVP and COO for the Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research Ms. Eastham has also served as SVP and CFO of Diversa Corporation

  40. Slide 40: James R. Gavin III, M.D., Ph.D.

    James R. Gavin III, M.D., Ph.D. Leader in diabetes having been the former National Chairman of the National Diabetes Education Program and past President of the American Diabetes Association Dr. Gavin is a Clinical Professor of Medicine at Emory University School of Medicine and Clinical Professor o

  41. Slide 41: Jay Skyler, MD, MACP

    Jay Skyler, MD, MACP Leader in the diabetes and medical communities, having served as the President of the American Diabetes Association Dr. Skyler is a professor of Medicine, Pediatrics and Psychology, in the Division of Endocrinology Diabetes and Metabolism and the Associate Director for Academic

  42. Slide 42: Joseph Sullivan, J.D., M.B.A.

    Joseph Sullivan, J.D., M.B.A. Expertise in healthcare policy, serving as the Chairman of the Board of Advisors of RAND Health Mr. Sullivan has extensive healthcare experience serving as the Chairman of the Board of Advisors of the UCLA Medical Center and as the Chairman of the Board of Advisors of R

  43. Slide 43: James Wilson, M.B.A.

    James Wilson, M.B.A. Broad leadership and diabetes experience Mr. Wilson formerly was President and CEO of Syntex Corporation Mr. Wilson has significant operating experience in diabetes having been CEO of LifeScan, a glucose monitoring company He also has strong board experience serving as Chairman

Amylin Pharmaceuticals — Proxy Contest (May 2009) on 6ix